Abstract
Outbreaks and sporadic cases of meningococcal disease among college students have prompted consideration of a policy of routine vaccination for this group. Purchase and administration of the vaccine for routine vaccination would cost $56 million per year. Savings in medical care and indirect costs would not equal this amount unless the annual rate of disease among students is at least 6.5/100,000. The actual rate among students is unknown; however, surveillance data suggest it could not be more than 1.3/100,000. At rates near this estimate, the net cost of the program would be approximately $45 million annually. More cost-effective prevention strategies might be yielded by further studies to identify students at substantial risk of meningococcal disease, or by the development of a conjugate serogroup C vaccine that could be administered during infancy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Artenstein M. S., Gold R., Zimmerly J. G., Wyle F. A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970 Feb 19;282(8):417–420. doi: 10.1056/NEJM197002192820803. [DOI] [PubMed] [Google Scholar]
- Cochi S. L., Broome C. V., Hightower A. W. Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine. A cost-effectiveness model of strategy assessment. JAMA. 1985 Jan 25;253(4):521–529. [PubMed] [Google Scholar]
- DODGE P. R., SWARTZ M. N. BACTERIAL MENINGITIS--A REVIEW OF SELECTED ASPECTS. II. SPECIAL NEUROLOGIC PROBLEMS, POSTMENINGITIC COMPLACATIONS AND CLINICOPATHOLOGICAL CORRELATIONS. N Engl J Med. 1965 May 6;272:954–CONTD. doi: 10.1056/NEJM196505062721806. [DOI] [PubMed] [Google Scholar]
- Eisenberg J. M. Clinical economics. A guide to the economic analysis of clinical practices. JAMA. 1989 Nov 24;262(20):2879–2886. doi: 10.1001/jama.262.20.2879. [DOI] [PubMed] [Google Scholar]
- Hodgson T. A., Meiners M. R. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982 Summer;60(3):429–462. [PubMed] [Google Scholar]
- Jadavji T., Biggar W. D., Gold R., Prober C. G. Sequelae of acute bacterial meningitis in children treated for seven days. Pediatrics. 1986 Jul;78(1):21–25. [PubMed] [Google Scholar]
- Keane W. M., Potsic W. P., Rowe L. D., Konkle D. F. Meningitis and hearing loss in children. Arch Otolaryngol. 1979 Jan;105(1):39–44. doi: 10.1001/archotol.1979.00790130043010. [DOI] [PubMed] [Google Scholar]
- Lepow M. L., Goldschneider I., Gold R., Randolph M., Gotschlich E. C. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics. 1977 Nov;60(5):673–680. [PubMed] [Google Scholar]
- Rice D. P., Hodgson T. A., Kopstein A. N. The economic costs of illness: a replication and update. Health Care Financ Rev. 1985 Fall;7(1):61–80. [PMC free article] [PubMed] [Google Scholar]
- Sander J., Bay D., Gedde-Dahl T. W., Borchgrevink H. M., Frøholm L. O., Oftedal S. I., Vandvik B. Late sequelae after meningococcal disease. A controlled study in young men. NIPH Ann. 1984 Jun;7(1):3–11. [PubMed] [Google Scholar]
- Weiss K. B., Gergen P. J., Hodgson T. A. An economic evaluation of asthma in the United States. N Engl J Med. 1992 Mar 26;326(13):862–866. doi: 10.1056/NEJM199203263261304. [DOI] [PubMed] [Google Scholar]
- Willems J. S., Sanders C. R., Riddiough M. A., Bell J. C. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med. 1980 Sep 4;303(10):553–559. doi: 10.1056/NEJM198009043031004. [DOI] [PubMed] [Google Scholar]